氧化磷脂、脂蛋白(a)与急性冠脉综合征后的心血管结局
在ODYSSEY OUTCOMES试验中,测量了11 630例急性冠脉综合征患者基线及5 185例随机后4个月的OxPL-apoB和Lp(a)水平。中位随访2.9年,阿利西尤单抗降低OxPL-apoB中位数13.0%和Lp(a)26.2%。在安慰剂组,基线OxPL-apoB每倍增与MACE风险相关(HR 1.081),但加入Lp(a)后该关联不再显著;阿利西尤单抗组中两者均与MACE无关。
要点
- 基线OxPL-apoB升高预测MACE,但该关联依赖Lp(a)水平。
- 阿利西尤单抗显著降低OxPL-apoB和Lp(a),且消除OxPL-apoB与MACE的关联。
- OxPL-apoB与Lp(a)及治疗存在三重交互作用,提示Lp(a)较低时OxPL-apoB独立预测风险。
核心结论
- 在接受优化他汀治疗的近期急性冠脉综合征患者中,升高的OxPL-apoB水平预测MACE,但阿利西尤单抗消除了这一关系。
- 安慰剂组中OxPL-apoB与Lp(a)的交互作用表明,当Lp(a)水平相对较低时,OxPL-apoB独立预测MACE。
研究设计与样本
- ODYSSEY OUTCOMES试验的事后分析,测量了11 630例参与者基线和5 185例参与者随机后4个月的OxPL-apoB和Lp(a)水平。
- 使用比例风险模型评估log2转换的OxPL-apoB和Lp(a)与MACE的关联,并调整基线协变量。
主要发现
- 中位随访2.9年,中位年龄58岁,女性占23.9%。
- 阿利西尤单抗较安慰剂降低OxPL-apoB中位数13.0%和Lp(a)26.2%(均P<0.0001)。
- 安慰剂组中,基线OxPL-apoB每倍增与MACE的风险比(HR)为1.081(95% CI 1.026-1.139;P=0.0034)。
- 在模型中加入Lp(a)后,OxPL-apoB与MACE的关联不再显著;阿利西尤单抗组中OxPL-apoB和Lp(a)均与MACE无显著关联。
- 连续log2 OxPL-apoB、按中位数分层的Lp(a)和治疗组之间存在显著三重交互作用(Pinteraction=0.0023)。
临床怎么用
- 对于近期急性冠脉综合征且接受优化他汀治疗的患者,检测OxPL-apoB和Lp(a)可能有助于风险分层。
- 阿利西尤单抗可降低OxPL-apoB和Lp(a),并可能减弱OxPL-apoB相关的残余风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) reflect pro-inflammatory properties of Lp(a) (lipoprotein(a)). The effect of OxPL-apoB on major adverse cardiovascular events (MACE) in patients with acute coronary syndrome in recent the era is not known. METHODS: OxPL-apoB levels and Lp(a) were measured in 11 630 participants before and 5185 participants 4 months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. Proportional hazards models adjusted for baseline covariates evaluated associations between log2-transformed OxPL-apoB and Lp(a) with MACEs. Interactions between the 2 biomarkers and treatment were also evaluated. RESULTS: Participants were followed for a median 2.9 years; the median age was 58 years, and 23.9% were female. Alirocumab reduced median placebo-adjusted OxPL-apoB by 13.0% and Lp(a) by 26.2% (both P<0.0001). In the placebo group, a doubling of baseline OxPL-apoB was associated with a hazard ratio (HR) of 1.081 (95% CI, 1.026-1.139; P=0.0034) for MACEs. Addition of Lp(a) to the model relegated the relationship of OxPL-apoB insignificant. In the alirocumab group, neither OxPL-apoB nor Lp(a) remained significantly associated with MACEs. A significant 3-way interaction was present among continuous log2 OxPL-apoB, Lp(a) stratified at the median, and treatment group on MACEs (Pinteraction=0.0023) so that, in the placebo group, increasing OxPL-apoB was associated with higher risk of MACEs when Lp(a) was below the median concentration but not above. In the alirocumab group, OxPL-apoB was not related to MACE risk irrespective of Lp(a) concentration. CONCLUSIONS: In patients with recent acute coronary syndrome receiving optimized statin treatment, elevated OxPL-apoB levels predicted MACEs, a relationship abrogated by alirocumab. The interaction of OxPL-apoB and Lp(a) in the placebo group indicates that OxPL-apoB independently predicts MACEs when Lp(a) levels are relatively low. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT001747 and NCT01663402.
引用
- Tsimikas, Szarek, Cobbaert, et al. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome. Circulation. 2025. PMID: 41321238. doi:10.1161/CIRCULATIONAHA.125.073855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。